Mismatch Repair Proteins in Recurrent Prostate Cancer

Advances in Clinical Chemistry

Volumn 60, Issue , 2013, Pages 65-84

  Jarzen, John ^a   Diamanduros, Andrew ^a   Scarpinato, Karin D ^a  

^a GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

DNA repair proteins; Mismatch repair; Mutation; MutS homolog; Prostate cancer

Indexed keywords

EID: 84875090043     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-407681-5.00002-7     Document Type: Chapter

References (91)

1. Preston B.D., Albertson T.M., Herr A.J. DNA replication fidelity and cancer. Semin. Cancer Biol. 2010, 20:281-293.
2. Modrich P., Lahue R. Mismatch repair in replication fidelity, genetic recombination and cancer biology. Annu. Rev. Biochem. 1996, 65:101-133.
3. Umar A., Risinger J.I., Glaab W.E., Tindall K.R., Barrett J.C., Kunkel T.A. Functional overlap in mismatch repair by human MSH3 and MSH6. Genetics 1998, 148:1637-1646.
4. Buermeyer A.B., Deschenes S.M., Baker S.M., Liskay R.M. Mammalian DNA mismatch repair. Annu. Rev. Genet. 1999, 33:533-564.
5. Wang T.F., Kleckner N., Hunter N. Functional specificity of MutL homologs in yeast: evidence for three Mlh1-based heterocomplexes with distinct roles during meiosis in recombination and mismatch correction. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13914-13919.
6. Chen P.C., Dudley S., Hagen W., Dizon D., Paxton L., Reichow D., Yoon S.R., Yang K., Arnheim N., Liskay R.M., Lipkin S.M. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res. 2005, 65:8662-8670.
7. Kunkel T.A., Erie D.A. DNA mismatch repair. Annu. Rev. Biochem. 2005, 74:681-710.
8. Iyer R.R., Pluciennik A., Burdett V., Modrich P. DNA mismatch repair: functions and mechanisms. Chem. Rev. 2006, 106:302-323.
9. Kadyrov F.A., Dzantiev L., Constantin N., Modrich P. Endonucleolytic function of MutLalpha in human mismatch repair. Cell 2006, 126:297-308.
10. Isaacs R.J., Spielmann H.P. A model for initial DNA lesion recognition by NER and MMR based on local conformational flexibility. DNA Repair 2004, 3:455-464.
11. Wang H., Yang Y., Schofield M.J., Du C., Fridman Y., Lee S.D., Larson E.D., Drummond J.T., Alani E., Hsieh P., Erie D.A. DNA bending and unbending by MutS govern mismatch recognition and specificity. Proc. Natl. Acad. Sci. U.S.A. 2003, 200:14822-14827.
12. Erdeniz N., Nguyen M., Deschenes S.M., Liskay R.M. Mutations affecting a putative MutL[alpha] endonuclease motif impact multiple mismatch repair functions. DNA Repair 2007, 6:1463-1470.
13. Topping R.P., Wilkinson J.C., Scarpinato K.D. Mismatch repair protein deficiency compromises cisplatin-induced apoptotic signaling. J. Biol. Chem. 2009, 284:14029-14039.
14. Kat A., Thilly W.G., Fang W.-H., Longley M.J., Li G.-M., Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:6424-6428.
15. Branch P., Aquilina G., Bignami M., Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 1993, 362:652-654.
16. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 2001, 22:1931-1937.
17. Bignami M., Casorelli I., Karran P. Mismatch repair and response to DNA-damaging antitumour therapies. Eur. J. Cancer 2003, 39:2142-2149.
18. Stojic L., Brun R., Jiricny J. Mismatch repair and DNA damage signaling. DNA Repair 2004, 3:1091-1101.
19. O'Brien V., Bron R. Signalling cell cycle arrest and cell death through the MMR system. Carcinogenesis 2006, 27:682-692.
20. Wang J.Y., Edelmann W. Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell 2006, 9:417-418.
21. Papouli E., Cejka P., Jiricny J. Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res. 2004, 64:3391-3394.
22. Ni T.T., Marsischky G.T., Kolodner R.D. MSH2 and MSH6 are required for removal of adenine misincorporated opposite 8-oxo-guanine in S. cerevisiae. Mol. Cell 1999, 4:439-444.
23. Colussi C., Parlanti E., Degan P., Aquilina G., Barnes D., Macpherson P., Karran P., Crescenzi M., Dogliotti E., Bignami M. The mammalian mismatch repair pathway removes DNA 8-oxodGMP incorporated from the oxidized dNTP pool. Curr. Biol. 2002, 12:912-918.
24. Sekiguchi M., Tsuzuki T. Oxidative nucleotide damage: consequences and prevention. Oncogene 2002, 21:8895-8904.
25. Casorelli I., Russo M.T., Bignami M. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med Chem. 2008, 8:368-380.
26. Drotschmann K., Topping R.P., Clodfelter J.E., Salsbury F.R. Mutations in the nucleotide-binding domain of MutS homologs uncouple cell death from cell survival. DNA Repair 2004, 3:729-742.
27. Salsbury F.R., Clodfelter J.E., Gentry M.B., Hollis T., Scarpinato K.D. The molecular mechanism of DNA damage recognition by MutS homologs and its consequences for cell death response. Nucleic Acids Res. 2006, 24:2173-2185.
28. Lin D.P., Wang Y., Scherer S.J., Clark A.B., Yang K., Avdievich E., Jin B., Werling U., Parris T., Kurihara N., Umar A., Kucherlapati R., Lipkin M., Kunkel T.A., Edelmann W. An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res. 2004, 64:517-522.
29. Seifert M., Reichrath J. The role of the human DNA mismatch repair gene hMSH2 in DNA repair, cell cycle control and apoptosis: implications for pathogenesis, progression and therapy of cancer. J. Mol. Histol. 2006, 37:301-307.
30. Kinsella T.J. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin. Cancer Res. 2009, 15:1853-1859.
31. Leach F.S., Nicolaides N.C., Papadopoulos N., Liu B., Jen J., Parsons R., Peltomaki P., Sistonen P., Aaltonen L.A., Nystrom-Lahti M., et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 1993, 75:1215-1225.
32. Wolf B., Gruber S., Henglmueller S., Kappel S., Bergmann M., Wrba F., Karner-Hanusch J. Efficiency of the revised Bethesda guidelines (2003) for the detection of mutations in mismatch repair genes in Austrian HNPCC patients. Int. J. Cancer 2006, 118:1465-1470.
33. Vasen H.F. Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment. Pharmacol. Ther. 2007, 26(Suppl. 2):113-126.
34. Balmana J., Balaguer F., Castellvi-Bel S., Steyerberg E.W., Andreu M., llor X., Jover R., Castells A., Syngal S. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. J. Med. Genet. 2008, 45:557-563.
35. Strand M., Prolla T.A., Liskay R.M., Petes T.D. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature 1993, 365:274-276.
36. Peltomaki P., Lothe R.A., Aaltonen L.A., Pylkkanen L., Nystrom-Lahti M., Seruca R., David L., Holm R., Ryberg D., et al. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res. 1993, 53:5853-5855.
37. Boland C.R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010, 138:2073-2087.
38. Duval A., Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. Cancer Res. 2002, 62:2447-2454.
39. Lawes D.A., SenGupta S., Boulos P.B. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur. J. Surg. Oncol. 2003, 29:201-212.
40. Parsons R., Li G.-M., Longley M.H., Fang W.-H., Papadopulos N., Jen J., et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell 1993, 75:1227-1236.
41. Bhattacharyya N.P., Skandalis A., Ganesh A., Groden J., Meuth M. Mutator phenotypes in human colorectal carcinoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:6319-6323.
42. Eshleman J.R., Lang E.Z., Bowerfind G.K., Parsons R., Vogelstein B., Willson J.K., et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 1995, 10:33-37.
43. Bielas J.H., Loeb K.R., Rubin B.P., True L.D., Loeb L.A. Human cancers express a mutator phenotype. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:18238-18242.
44. Klein C.A. Random mutations, selected mutations: a PIN opens the door to new genetic landscapes. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:18033-18034.
45. Abdel-Rahman W.M., Peltomaki P. Lynch syndrome and related familial colorectal cancer. Crit. Rev. Oncog. 2008, 14:1-22.
46. Siegel R., Ward E., Brawley O., Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 2011, 61:212-236.
47. Boland C.R., Sato J., Saito K., Carethers J.M., Marra G., Laghi L., Chauhan D.P. Genetic instability and chromosomal aberrations in colorectal cancer: a review of the current models. Cancer Detect. Prev. 1998, 22:377-382.
48. Gao X., Wu N., Grignon D., Zacharek A., Liu H., Salkowski A., Li G., Sakr W., Sarkar F., Porter A.T., et al. High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 1994, 9:2999-3003.
49. Uchida T., Wada C., Wang C., Ishida H., Egawa S., Yokoyama E., Ohtani H., Koshiba K. Microsatellite instability in prostate cancer. Oncogene 1995, 10:1019-1022.
50. Egawa S., Uchida T., Suyama K., Wang C., Ohori M., Irie S., Iwamura M., Koshiba K. Genomic instability of microsatellite repeats in prostate cancer: relationship to clinicopathological variables. Cancer Res. 1995, 55:2418-2421.
51. Suzuki H., Komiya A., Akimoto S., Shiraishi T., Yatani R., Igarashi T., Shimazaki J. Microsatellite instability and other molecular abnormalities in human prostate cancer. Jpn. J. Cancer Res. 1995, 86:956-961.
52. Gao X., Porter A.T., Honn K.V. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv. Exp. Med. Biol. 1997, 407:41-53.
53. Rohrbach H., Haas C.J., Baretton G.B., Hirschmann A., Diebold J., Behrendt R.P., Lohrs U. Microsatellite instability and loss of heterozygosity in prostatic carcinomas: comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases. Prostate 1999, 40:20-27.
54. Ahman A.K., Jonsson B.A., Damber J.E., Bergh A., Emanuelsson M., Gronberg H. Low frequency of allelic imbalance at the prostate cancer susceptibility loci HPC1 and 1p36 in Swedish men with hereditary prostate cancer. Genes Chromosomes Cancer 2000, 29:292-296.
55. Burger M., Denzinger S., Hammerschmied C.G., Tannapfel A., Obermann E.C., Wieland W.F., Hartmann A., Stoehr R. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer. J. Mol. Med. 2006, 84:833-841.
56. von Knobloch R., Konrad L., Barth P.J., Brandt H., Wille S., Heidenreich A., Moll R., Hofmann R. Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping. Clin. Cancer Res. 2004, 10:1064-1073.
57. Chen Y., Wang J., Fraig M.M., Metcalf J., Turner W.R., Bissada N.K., Watson D.K., Schweinfest C.W. Defects of DNA mismatch repair in human prostate cancer. Cancer Res. 2001, 61:4112-4121.
58. Bauer C.M., Ray A.M., Halstead-Nussloch B.A., Dekker R.G., Raymond V.M., Gruber S.B., Cooney K.A. Hereditary prostate cancer as a feature of Lynch syndrome. Fam. Cancer 2011, 10:37-42.
59. Yegnasubramanian S., Kowalski J., Gonzalgo M.L., Zahurak M., Piantadosi S., Walsh P.C., bova G.S., De Marzo A.M., Isaacs W.B., Nelson W.G. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004, 64:1975-1986.
60. Cejka P., Stojic L., Mojas N., Russell A.M., Heinimann K., Cannavo E., di Pietro M., Marra G., Jiricny J. Methylation-induced G(2)/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J. 2003, 22:2245-2254.
61. Fishel R., Lescoe M.K., Rao M.R., Copeland N.G., Jenkins N.A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993, 75:1027-1038.
62. Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., Lescoe M.K., Kane M., Earabino C., Lipford J., Lindblom A., et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994, 368:258-261.
63. Nicolaides N.C., Papadopoulos N., Liu B., Wei Y.F., Carter K.C., Ruben S.M., Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994, 371:75-80.
64. Papadopoulos N., Nicolaides N.C., Wei Y.F., Ruben S.M., Carter K.C., Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D. Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263:1625-1629.
65. Yeh C.C., Lee C., Dahiya R. DNA mismatch repair enzyme activity and gene expression in prostate cancer. Biochem. Biophys. Res. Commun. 2001, 285:409-413.
66. Chen Y., Wang J., Fraig M.M., Henderson K., Bissada N.K., Watson D.K., Schweinfest C.W. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int. J. Oncol. 2003, 22:1033-1043.
67. Strom S.S., Spitz M.R., Yamamura Y., Babaian R.J., Scardino P.T., Wei Q. Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate 2001, 47:269-275.
68. Prtilo A., Leach F.S., Markwalder R., Kappeler A., Burkhard F.C., Cecchini M.G., Studer U.E., Thalmann G.N. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J. Urol. 2005, 174:1814-1818.
69. Velasco A., Hewitt S.M., Albert P.S., Hossein M., Rosenberg H., Martinez C., Sagalowsky A.I., McConnell J.D., Marston W., Leach F.S. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer 2002, 94:690-699.
70. Chuang S.T., Adley B., Han M., Lin F., Yang X.J., Catalona W.J. Mutant L Homologue 1 (MLH1): a possible new immunohistochemical marker for prostatic cancer. Histopathology 2008, 52:247-250.
71. Norris A.M., Woodruff R.D., D'Agostino R.B., Clodfelter J.E., Scarpinato K.D. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate 2007, 67:214-225.
72. Brothman A.R., Peehl D.M., Patel A.M., McNeal J.E. Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res. 1990, 50:3795-3803.
73. Alcaraz A., Takahashi S., Brown J.A., Herath J.F., Bergstralh E.J., Larson-Keller J.J., Lieber M.M., Jenkins R.B. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res. 1994, 54:3998-4002.
74. Bandyk M.G., Zhao L., Troncoso P., Pisters L.L., Palmer J.L., von Eschenbach A.C., Chung L.W., Liang J.C. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 1994, 9:19-27.
75. van den Berg C., Guan X.Y., von Hoff D., Jenkins R., Bittner, Kallioniemi O., Visakorpi, McGill, Herath J., et al. DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin. Cancer Res. 1995, 1:11-18.
76. Leach F.S., Velasco A., Hsieh J.T., Sagalowsky A.I., McConnell J.D. The mismatch repair gene hMSH2 is mutated in the prostate cancer cell lines LNCaP. J. Urol. 2000, 164:1830-1833.
77. Rass K., Gutwein P., Welter C., Meineke V., Tilgen W., Reichrath J. DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines. Histochem. J. 2001, 33:459-467.
78. Srivastava T., Chattopadhyay P., Mahapatra A.K., Sarcar C., Sinha S. Increased hMSH2 protein expression in glioblastoma multiforme. J. Neurooncol 2004, 66:51-57.
79. Marra G., Chang C.L., Laghi L.A., Chauhan D.P., Young D., Boland C.R. Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells. Oncogene 1996, 13:2189-2196.
80. Kang X., Chen W., Kim R.H., Kang M.K., Park N.H. Regulation of the hTERT promoter activity by MSH2, the hnRNPs K and D, and GRHL2 in human oral squamous cell carcinoma cells. Oncogene 2009, 28:565-574.
81. Martin L., Coffey M., Lawler M., Hollywood D., Marignol L. DNA mismatch repair and the transition to hormone independence in breast and prostate cancer. Cancer Lett. 2010, 291:142-149.
82. Norris A.M., Gentry M., Peehl D.M., D'Agostino R., Scarpinato K.D. The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy. Cancer Epidemiol. Biomarkers Prev. 2009, 18:57-64.
83. Langeberg W.J., Kwon E.M., Koopmeiners J.S., Ostrander E.A., Stanford J.L. Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes. Cancer Epidemiol. Biomarkers Prev. 2010, 19:258-264.
84. Grindedal E.M., Moller P., Eeles R., Stormorken A.T., Bowitz-Lothe I.M., Landro S.M., Clark N., Kvale R., Shaley S., Maehle L. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2460-2467.
85. Hara T., Kouno J., Nakamura K., Kusaka M., Yamaoka M. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate 2005, 65:268-275.
86. Li H.R., Shagisultanova E.I., Yamashita K., Piao Z., Perucho M., Malkhosyan S.R. Hypersensitivity of tumor cell lines with microsatellite instability to DNA double strand break producing chemotherapeutic agent bleomycin. Cancer Res. 2004, 64:4760-4767.
87. Yang J.L., Qu X.J., Kohn E.C., Friedlander M.L. Selective sensitivity to carboxyamidotrazole by human tumor cell lines with DNA mismatch repair deficiency. Int. J. Cancer 2008, 123:258-263.
88. Chen F., Arseven O.K., Cryns V.L. Proteolysis of the mismatch repair protein MLH1 by caspase-3 promotes DNA damage-induced apoptosis. J. Biol. Chem. 2004, 279:27542-27548.
89. Watanabe M., Ushijima T., Shiraishi T., Yatani R., Shimazaki J., Kotake T., Sugimura T., Nagao M. Genetic alterations of androgen receptor gene in Japanese human prostate cancer. Jpn. J. Clin. Oncol. 1997, 27:389-393.
90. Miyamoto T., Shiozawa T., Kashima H., Feng Y.Z., Suzuki A., Kurai M., Nikaido T., Konishi I. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells. Endocrinology 2006, 147:4863-4870.
91. Jim P., Lu X.J., Sheng J.Q., Fu L., Meng X.M., Wang X., Shi T.P., Li S.R., Rao J. Estrogen stimulates the expression of mismatch repair gene hMLH1 in colonic epithelial cells. Cancer Prev. Res. 2010, 3:910-916.